Centre Hospitalier De Bourg-En-Bresse — Clinical Trial Site

27 Registered trials

10 Currently recruiting

Organisation

Centre Hospitalier De Bourg-En-Bresse

Location

Bourg En Bresse, France

Identifier

ORG-100044448

Address

900 Route De Paris, 01012, France

Departments

Intensive care
Intensive Care Unit
Médecine Intensive - Réanimation
Medecine intensive care unit
Medical oncology
Medical Oncology Department
Neurology
Onco-Hématologie
Onco-Hematology
Oncologie
Oncologie médicale
Oncology
Oncology-Hematology
Réanimation – Soins continus
Réanimation Polyvalente
Service d'Oncologie Médicale
Service de Pédiatrie
Unité de soins intensifs

Clinical trials at this site (27)

Search interface

A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-assoc… Pending

2023-510075-63-00 Patients with ventilator-associated tracheobronchitis 5
MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending

2025-521371-31-00 Sepsis 4
TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending

2025-524213-84-00 Patients with advanced or metastatic ER+ HER2- breast c 5
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial Pending

2025-524976-40-00 patients with influenza-induced acute hypoxemic respira 5
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5 2026-04-23
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
Apneic oxygenation with high-flow nasal oxygenation after preoxygenation with noninvasive ventilation before intubation in hypoxemic patient… Recruiting

2024-514949-11-00 Hypoxemic acute respiratory failure 5 2026-03-18
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Multiple Myeloma 5 2025-07-09
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
Weaning protocol for high-flow nasal oxygen therapy in the ICU - Multicenter randomized controlled trial. HiFloWEAN Recruiting

2023-504366-36-00 de novo acute respiratory failure 5 2024-02-17
OBEVIDOS “Treatment of vitamin D deficit in obese children and adolescents: an open label randomized controlled study comparing the efficacy… Recruiting

2023-507089-18-00 Obese children and adolescents 5 2023-11-24
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Patients with untreated metastatic Estrogen Receptor po 5 2020-06-11
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended

2024-516847-23-00 ER-positive and HER2-negative metastatic or locally adv 4 2019-08-27
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05